Quest Diagnostics Inc (DGX)

$182.18 -1.05 (-0.57%)
Market Cap 20.38B
Revenue (ttm) 9.87B
Net Income (ttm) 871.00M
EPS (ttm) N/A
PE Ratio 18.75
Forward PE 18.49
Profit Margin 8.82%
Debt to Equity Ratio 0.78
Volume 867,000
Avg Vol 888,926
Day's Range N/A - N/A
Shares Out 111.24M
Stochastic %K 15%
Beta 0.56
Analysts Sell
Price Target $195.18

Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 973 520 2700
Address:
500 Plaza Drive, Secaucus, United States
Bazzzigar
Bazzzigar Oct. 24 at 10:59 PM
$DGX hold long term
0 · Reply
Bazzzigar
Bazzzigar Oct. 24 at 6:23 PM
$DGX few more
0 · Reply
Small_time_trader
Small_time_trader Oct. 22 at 7:36 PM
$DGX Don’t sweat PAMA If PAMA is not delayed, many smaller labs instantly would be non - profitable and close their doors, big commercial labs like DGX would swoop in and grab the work. most likely Pama will continue to be pushed out until substantial changes are made to the pieces impacting laboratory medicine. Either way DGX wins
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 4:59 PM
Barclays has adjusted their stance on Quest Diagnostics ( $DGX ), setting the rating to Equal-Weight with a target price of 190 → 195.
0 · Reply
Bazzzigar
Bazzzigar Oct. 22 at 3:13 PM
$DGX sector up
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 2:09 PM
Truist Securities updates rating for Quest Diagnostics ( $DGX ) to Hold, target set at 195 → 205.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:57 PM
Leerink Partners has updated their rating for Quest Diagnostics ( $DGX ) to Outperform with a price target of 210.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:39 PM
Jefferies updates rating for Quest Diagnostics ( $DGX ) to Buy, target set at 200 → 215.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:37 PM
Jefferies has updated their rating for Quest Diagnostics ( $DGX ) to Buy with a price target of 200.
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 21 at 7:46 PM
$DGX Share Price: $184.70 Contract Selected: Feb 20, 2026 $185 Calls Buy Zone: $7.48 – $9.24 Target Zone: $13.89 – $16.98 Potential Upside: 75% ROI Time to Expiration: 121 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on DGX
Quest Diagnostics: Strong Q3, Steady (Not Spectacular) Growth Ahead

Oct 22, 2025, 3:10 PM EDT - 2 days ago

Quest Diagnostics: Strong Q3, Steady (Not Spectacular) Growth Ahead

Quest Diagnostics Analysts Increase Their Forecasts After Q3 Earnings

Oct 22, 2025, 1:19 PM EDT - 3 days ago

Quest Diagnostics Analysts Increase Their Forecasts After Q3 Earnings

Quest Diagnostics Incorporated (DGX) Q3 2025 Earnings Call Transcript

Oct 21, 2025, 11:54 AM EDT - 4 days ago

Quest Diagnostics Incorporated (DGX) Q3 2025 Earnings Call Transcript

Quest Diagnostics raises annual profit and revenue forecasts on lab test demand

Oct 21, 2025, 7:16 AM EDT - 4 days ago

Quest Diagnostics raises annual profit and revenue forecasts on lab test demand

Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

Oct 21, 2025, 6:45 AM EDT - 4 days ago

Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

Quest Diagnostics: Investing In Healthcare's Future Today

Oct 6, 2025, 12:49 AM EDT - 19 days ago

Quest Diagnostics: Investing In Healthcare's Future Today

Quest Diagnostics Incorporated (DGX) Presents at Jefferies 2025 Healthcare Services Conference Transcript

Sep 29, 2025, 7:07 PM EDT - 25 days ago

Quest Diagnostics Incorporated (DGX) Presents at Jefferies 2025 Healthcare Services Conference Transcript

Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

Sep 25, 2025, 10:00 AM EDT - 4 weeks ago

Quest Diagnostics to Release Third Quarter 2025 Financial Results on October 21, 2025

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

Sep 24, 2025, 8:05 AM EDT - 4 weeks ago

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

GH

Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration

Sep 23, 2025, 7:07 AM EDT - 4 weeks ago

Quest Diagnostics to Improve Laboratory Testing Experience with Industry-First Epic Collaboration

Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer

Sep 22, 2025, 8:07 AM EDT - 4 weeks ago

Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer

WHOOP to Bring Clinical Lab Testing from Quest Diagnostics to the WHOOP App

Sep 18, 2025, 9:00 AM EDT - 5 weeks ago

WHOOP to Bring Clinical Lab Testing from Quest Diagnostics to the WHOOP App

Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference

Sep 15, 2025, 6:21 PM EDT - 5 weeks ago

Quest Diagnostics to Speak at the Jefferies Healthcare Services Conference

Quest Diagnostics Incorporated (DGX) Presents At Baird Global Healthcare Conference 2025 Transcript

Sep 10, 2025, 1:16 PM EDT - 6 weeks ago

Quest Diagnostics Incorporated (DGX) Presents At Baird Global Healthcare Conference 2025 Transcript

Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering

Sep 4, 2025, 9:32 AM EDT - 7 weeks ago

Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering

Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index

Sep 2, 2025, 6:27 AM EDT - 7 weeks ago

Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index

Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan

Aug 26, 2025, 9:00 AM EDT - 2 months ago

Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan

FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics

Aug 25, 2025, 8:52 AM EDT - 2 months ago

FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics

Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference

Aug 15, 2025, 6:14 PM EDT - 2 months ago

Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference

Quest Diagnostics Declares Quarterly Cash Dividend

Aug 13, 2025, 6:35 PM EDT - 2 months ago

Quest Diagnostics Declares Quarterly Cash Dividend

Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types

Aug 7, 2025, 9:08 AM EDT - 2 months ago

Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types

Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care

Aug 5, 2025, 8:33 AM EDT - 2 months ago

Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care

Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing

Jul 29, 2025, 8:52 AM EDT - 3 months ago

Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing

PACB

Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks

Jul 22, 2025, 1:10 PM EDT - 3 months ago

Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks

Quest Diagnostics Incorporated (DGX) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 12:22 PM EDT - 3 months ago

Quest Diagnostics Incorporated (DGX) Q2 2025 Earnings Call Transcript

Quest Diagnostics raises annual forecasts on strong diagnostic testing demand

Jul 22, 2025, 7:17 AM EDT - 3 months ago

Quest Diagnostics raises annual forecasts on strong diagnostic testing demand

Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

Jul 22, 2025, 6:47 AM EDT - 3 months ago

Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

Quest Diagnostics Introduces Testing for Oropouche Virus

Jul 15, 2025, 7:57 AM EDT - 3 months ago

Quest Diagnostics Introduces Testing for Oropouche Virus

Quest Diagnostics: Buy Into Future Patient Demand, At An Undervalued Price Today

Jul 15, 2025, 7:36 AM EDT - 3 months ago

Quest Diagnostics: Buy Into Future Patient Demand, At An Undervalued Price Today

Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease

Jul 9, 2025, 8:24 AM EDT - 3 months ago

Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease

Quest Diagnostics Releases 2024 Corporate Responsibility Report

Jun 25, 2025, 9:07 AM EDT - 4 months ago

Quest Diagnostics Releases 2024 Corporate Responsibility Report

Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025

Jun 23, 2025, 10:52 AM EDT - 4 months ago

Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025

Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology

Jun 10, 2025, 8:03 AM EDT - 4 months ago

Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology

More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals

May 20, 2025, 8:52 AM EDT - 5 months ago

More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals

Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference

May 16, 2025, 1:11 PM EDT - 5 months ago

Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference

Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds

May 13, 2025, 6:03 AM EDT - 5 months ago

Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds

Quest Diagnostics: A Leader But Waiting For Better Price

May 3, 2025, 4:26 AM EDT - 6 months ago

Quest Diagnostics: A Leader But Waiting For Better Price

These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings

Apr 23, 2025, 1:17 PM EDT - 6 months ago

These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings

Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence

Apr 22, 2025, 12:09 PM EDT - 6 months ago

Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence

Quest Diagnostics Incorporated (DGX) Q1 2025 Earnings Call Transcript

Apr 22, 2025, 11:39 AM EDT - 6 months ago

Quest Diagnostics Incorporated (DGX) Q1 2025 Earnings Call Transcript

Quest beats quarterly profit estimates on strong demand for diagnostic tests

Apr 22, 2025, 7:37 AM EDT - 6 months ago

Quest beats quarterly profit estimates on strong demand for diagnostic tests

Quest Diagnostics earnings beat after March rebound in demand from slump early in the quarter

Apr 22, 2025, 7:01 AM EDT - 6 months ago

Quest Diagnostics earnings beat after March rebound in demand from slump early in the quarter

Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

Apr 22, 2025, 6:43 AM EDT - 6 months ago

Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease

Apr 9, 2025, 7:53 AM EDT - 7 months ago

Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease

8 Upcoming Dividend Increases During Volatile Times

Apr 4, 2025, 1:43 PM EDT - 7 months ago

8 Upcoming Dividend Increases During Volatile Times

AMT BKU GD KAI ORCL REIT RNP

Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening

Apr 2, 2025, 7:06 AM EDT - 7 months ago

Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening

Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025

Apr 1, 2025, 4:23 PM EDT - 7 months ago

Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025

Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day

Mar 19, 2025, 7:52 AM EDT - 7 months ago

Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day

Quest Diagnostics to Collaborate with Google Cloud to Streamline Data and Personalize Customer Experiences Using Generative AI

Mar 18, 2025, 9:00 AM EDT - 7 months ago

Quest Diagnostics to Collaborate with Google Cloud to Streamline Data and Personalize Customer Experiences Using Generative AI

Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics

Feb 24, 2025, 8:00 AM EST - 8 months ago

Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics

FMS

Bazzzigar
Bazzzigar Oct. 24 at 10:59 PM
$DGX hold long term
0 · Reply
Bazzzigar
Bazzzigar Oct. 24 at 6:23 PM
$DGX few more
0 · Reply
Small_time_trader
Small_time_trader Oct. 22 at 7:36 PM
$DGX Don’t sweat PAMA If PAMA is not delayed, many smaller labs instantly would be non - profitable and close their doors, big commercial labs like DGX would swoop in and grab the work. most likely Pama will continue to be pushed out until substantial changes are made to the pieces impacting laboratory medicine. Either way DGX wins
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 4:59 PM
Barclays has adjusted their stance on Quest Diagnostics ( $DGX ), setting the rating to Equal-Weight with a target price of 190 → 195.
0 · Reply
Bazzzigar
Bazzzigar Oct. 22 at 3:13 PM
$DGX sector up
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 2:09 PM
Truist Securities updates rating for Quest Diagnostics ( $DGX ) to Hold, target set at 195 → 205.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:57 PM
Leerink Partners has updated their rating for Quest Diagnostics ( $DGX ) to Outperform with a price target of 210.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:39 PM
Jefferies updates rating for Quest Diagnostics ( $DGX ) to Buy, target set at 200 → 215.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 8:37 PM
Jefferies has updated their rating for Quest Diagnostics ( $DGX ) to Buy with a price target of 200.
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 21 at 7:46 PM
$DGX Share Price: $184.70 Contract Selected: Feb 20, 2026 $185 Calls Buy Zone: $7.48 – $9.24 Target Zone: $13.89 – $16.98 Potential Upside: 75% ROI Time to Expiration: 121 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Small_time_trader
Small_time_trader Oct. 21 at 4:37 PM
$DGX Folks this was a good ole fashioned beat and raise with up beat messaging and feel. This dip in price IS A GIFT Expect it to go higher all day and quickly get back to 190 price
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 21 at 4:23 PM
$DGX
0 · Reply
induscapital
induscapital Oct. 21 at 2:18 PM
$LH $DGX If DGX is any cue then LH is going down from here till ER
0 · Reply
ZacksResearch
ZacksResearch Oct. 21 at 2:12 PM
$DGX beats Q3 predictions — what’s driving the gains? 🚀 Quest Diagnostics posted a 13% YoY increase in adjusted EPS, beating the Zacks Consensus Estimate by 3.59%, with revenues up 15.2% YoY to $2.82B, surpassing expectations. 📈 Discover the catalysts behind DGX’s growth here 👉 https://www.zacks.com/stock/news/2772997/quest-diagnostics-stock-up-on-q3-earnings-revenue-beat-margins-rise?cid=sm-stocktwits-2-2772997-body-16831&ADID=SYND_STOCKTWITS_TWEET_2_2772997_BODY_16831
0 · Reply
ZacksResearch
ZacksResearch Oct. 21 at 1:12 PM
$DGX delivers — and the market noticed. 🚀 Q3 earnings and revenue topped expectations, with margins on the rise — a solid combo that’s fueling investor confidence in the stock. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2772997/quest-diagnostics-stock-up-on-q3-earnings-revenue-beat-margins-rise?cid=sm-stocktwits-2-2772997-teaser-16824&ADID=SYND_STOCKTWITS_TWEET_2_2772997_TEASER_16824
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 10:38 AM
Enter: $DGX NOV 21 2025 $195 CALLS Buy in Price: $4.59 - $4.82 Take Profit: $9.78 Stop Bleeding: $4.04 ROI Potential: 113% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 20 at 1:21 PM
Enter: $DGX NOV 21 2025 $190 CALLS Buy in Price: $6.50 - $6.90 Take Profit: $10.33 Stop Bleeding: $5.72 ROI Potential: 59% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
PremarketAnalysis
PremarketAnalysis Oct. 20 at 10:11 AM
$DGX SignalEngine: MM Infl (Bearish) (1h + 5m), Algo Vol 49%, Org Vol 51%, Res 4.77, Sup 3.20 Algo Int: Sustained buying momentum reclaiming mid-channel.. watching for clean continuation above range. Momentum Feed: https://premarketanalysis.com/#momentum=DGX
0 · Reply
Small_time_trader
Small_time_trader Oct. 17 at 3:52 PM
$DGX 190 threshold bitch slapped dgx a few weeks ago…let’s see if it holds up better this time. Either way great ride up the last few years
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 1:53 PM
UBS has updated their rating for Quest Diagnostics ( $DGX ) to Neutral with a price target of 190.
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 1:27 PM
Mizuho updates rating for Quest Diagnostics ( $DGX ) to Outperform, target set at 190 → 210.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 12:30 AM
Enter: $DGX NOV 21 2025 $190 CALLS Buy in Price: $5.61 - $6.40 Take Profit: $10.55 Stop Bleeding: $4.94 ROI Potential: 88% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply